Abstract: Disclosed herein are microneedle devices, kits comprising the microneedle devices, and methods of using the microneedle devices. Specifically, disclosed is a device for transport of a material across a biological barrier of a subject comprising: a plurality of microneedles each having a base end and a tip, with at least one pathway disposed at or between the base end and the tip; a substrate to which the base ends of the microneedles are attached or integrated; and at least one reservoir which is in connection with the base ends of the microneedles array, wherein the reservoir comprises an agent delivery system, wherein the agent delivery system comprises an agent to be transported across the biological barrier, or a means for producing an agent to be transported across the biological barrier, and a means for detecting a physiological signal from the recipient.

Abstract: Disclosed are compositions and methods for delivering cardiac precursor cells to the site of cardiac injury. In one aspect, disclosed herein are microneedle patches for transport of a material across a biological barrier of a subject comprising a plurality of microneedles each having abase end and a tip; a substrate to which the base ends of the microneedles are attached or integrated; and a plurality of cardiac precursor cells (such as, for example, cardiac stem cells), as, well as, methods of using the same.

Abstract: Disclosed are compositions and methods for microneedle patches comprising diblock copolymer micelles designed for pH cascade and H2O2 triggered insulin delivery.

Abstract: Embodiments of the present disclosure relate generally to photoimmunotherapy for treating cancer. More particularly, the present disclosure provides photo-responsive dermal applicators that use transdermal microneedle arrays to administer an immunogenic composition and a photo-sensitive biological pigment to a subject to treat and/or prevent cancer. Photo-responsive dermal applicators of the present disclosure provide the ability to target cancerous tumors in a manner that is safer and less invasive than conventional means.

Abstract: Compositions comprising polymeric networks comprising combinations of small molecule hair growth agents and natural products (e.g., vesicles, such as stem cell-derived exosomes) are described. The polymeric network can, for example, comprise keratin crosslinked via intermolecular disulfide bonds. Alternatively, the polymeric network can comprise keratin or a derivative thereof and another crosslinked hydrophilic polymer. Microneedles, microneedle arrays, and skin patches comprising the compositions are also described, as are methods of treating hair loss and/or promoting hair growth using the microneedles, microneedle arrays and/or skin patches.

Abstract: A two-terminal resistive switching device (TTRSD) such as a non-volatile two-terminal memory device or a volatile two-terminal selector device can be formed according to a manufacturing process. The process can include forming an etch stop layer that is made of aluminum and can include forming a buffer layer below the etch stop layer and/or between the etch stop layer and a top electrode of the TTRSD.

Abstract: A composition comprising a bioresponsive (e.g., reactive oxygen species (ROS)-responsive), antibiotic- and/or absorbent-loaded polymeric network is described. In some cases, the composition can release the antibiotic loaded therein in response to ROS or another stimulus related to inflammation. Microneedles, microneedle arrays, and skin patches comprising the composition are also described, as well as methods of treating acne or other inflammatory/infectious skin conditions.

Abstract: A composition comprising an insulin-polymer conjugate and an insulin aptamer-glucagon conjugate is described. Depending upon the amount of insulin in the environment surrounding the composition, the insulin aptamer of the insulin aptamer-glucagon conjugate can bind to insulin in the insulin-polymer conjugate to form a non-covalent conjugate. When the amount of insulin in the surrounding environment rises, the insulin aptamer-glucagon conjugate can be released. Thus, the composition can be used to deliver glucagon in an insulin responsive manner. The composition can be loaded into microneedles, for example, to prepare microneedle arrays for skin patches. Methods of delivering glucagon to a subject are also described.

Abstract: Disclosed herein are microneedle devices, kits comprising the microneedle devices, and methods of using the microneedle devices. Specifically, disclosed is a device for transport of a material across a biological barrier of a subject comprising: a plurality of microneedles each having a base end and a tip, with at least one pathway disposed at or between the base end and the tip; a substrate to which the base ends of the microneedles are attached or integrated; and at least one reservoir which is in connection with the base ends of the microneedles array, wherein the reservoir comprises an agent delivery system, wherein the agent delivery system comprises an agent to be transported across the biological barrier, or a means for producing an agent to be transported across the biological barrier, and a means for detecting a physiological signal from the recipient.

Abstract: Disclosed are compositions and methods for treating cancer with a hydrogel matrix comprising a chemotherapeutic agent and a blockade inhibitor. Disclosed herein are bioresponsive hydrogel matrixes comprising a reactive oxygen species scavenger.

Abstract: Disclosed herein are methods of treating/inhibiting/reducing a non-immunogenic cancer in a subject or inducing blockade inhibitor susceptibility (such as, for example, PD-1/PDLI, CTLA-4/B7-1/2, and/or CD47/SIRPa inhibitor susceptibility) in a tumor in a subject with a cancer, said methods comprising administering to the subject a hydrogel matrix comprising a chemotherapeutic agent (including, but not limited to gemcitabine) and a blockade inhibitor (including, but not limited to aPD-1/PD-LI blockade inhibitor, such as, for example nivolumab, pembrolizumab, pidilizumab, atezolizumab, avelumab, durvalumab, and BMS-936559; a CTLA-4/B7-1/2 inhibitor such as, for example, Ipilimumab; and/or a CD47/SIRPa inhibitor such as, for example Hu5F9-G4, CVI, B6H12, 2D3, CC-90002, and TTI-621).

Abstract: Disclosed herein is a glucose-responsive insulin delivery system based on the interaction between the glucose-modified insulin and glucose transporters (GLUTs) on erythrocytes (or red blood cells, RBCs). After being conjugated with glucose, insulin can efficiently bind to RBC membranes. The binding is reversible in the setting of hyperglycemia, resulting in fast release of insulin and subsequent drop of blood glucose (BG) level in vivo. In some embodiments, the delivery vehicle can include: 1) intravenously injectable polymeric nanoparticles (˜100 nm in diameter) coated with RBC membrane and loaded with glucose-modified insulin and/or 2) painless microneedle (MN) patches loaded with the complex of GLUT and glucose-modified insulin.

Abstract: The present invention provides a semiconductor structure for forming a CMOS image sensor. The semiconductor structure includes at least a photodiode formed in the substrate for collecting photoelectrons, and the photodiode has a pinning layer, a first doped region and a second doped region in order from top to bottom in a height direction of the substrate. The semiconductor structure further includes a third doped region located in the substrate corresponding to a laterally extending region of the second doped region. The first doped region has an ion doping concentration greater than the ion doping concentration of the second doped region, the ion doping concentration of the second doped region is greater than the ion doping concentration of the third doped region, and the third doped region is in contact with the second doped region after diffusion. The present invention also provides a method of manufacturing the above-described semiconductor structure.

Abstract: The present disclosure relates to a thrombin-responsive closed-loop patch for prolonged heparin delivery in a feedback-controlled manner. The microneedle-based patch can sense the activated thrombin and subsequently release heparin to prevent coagulation in the blood flow. The patch can be transcutaneously inserted into skin without drug leaking and can sustainably regulate blood coagulation in response to thrombin.

Abstract: Disclosed are therapeutic agent delivery vehicle comprising a modified platelet comprising a therapeutic agent cargo and a targeting moiety and methods for treating cancer comprising administering the same to a subject.

Abstract: Disclosed are engineered nanovesicles and engineered platelets comprising an exogenous protein and methods for treating cancer comprising administering the same to a subject.

Abstract: A two-terminal resistive switching device (TTRSD) such as a non-volatile two-terminal memory device or a volatile two-terminal selector device can be formed according to a manufacturing process. The process can include forming an etch stop layer that is made of aluminum and can include forming a buffer layer below the etch stop layer and/or between the etch stop layer and a top electrode of the TTRSD.

Abstract: A composition comprising a glucose-responsive charge-switchable polymer is described. In the absence of glucose or under normoglycemic conditions, the positively charged polymer can be complexed with negatively charged therapeutic agents, such as insulin. Under hyperglycemic conditions, the positive charge of the polymer is reduced, and the polymer/therapeutic agent complex can disassemble, allowing the therapeutic agent to be released. Pharmaceutical compositions, nanoparticles, and microneedle arrays of the polymer and/or polymer/therapeutic agent complex and methods of treating diabetes are also described.

Abstract: A composition comprising an amphiphilic polymeric material that is both hydrogen peroxide- and hypoxia-sensitive is described. The composition can further include a glucose-oxidizing enzyme and insulin, a bioactive derivative thereof, and/or another therapeutic agent (e.g., another diabetes treatment agent). The polymeric material can form vesicles that comprise single or multiple layers of the polymeric material that enclose the glucose-oxidizing enzyme and the insulin, bioactive derivative and/or other therapeutic agent. The vesicles can be loaded into microneedles to, for example, prepare microneedle arrays for skin patches. Methods of delivering insulin to a subject using the compositions, vesicles, microneedles, and/or microneedle array skin patches are also described.

Abstract: Two-terminal memory devices can be formed in dielectric material that is electrically insulating and operates as a blocking layer to mitigate diffusion of material from a metal layer. A stack of layers of the two-terminal memory device can be covered with a liner layer that can comprise the dielectric material. Thus, in some implementations, the liner layer and the blocking layer can have a similar etch rate.